At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
TUTI-16 (1.0 mg) +1 morebiological
Likely dose
TUTI-16 (1.0 mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Study of TUTI-16 in Asymptomatic, HIV-1 Infected Subjects Effectively Controlled by Antiretroviral Therapy and the Effects on Viral Load During a Structured Treatment Interruption
In Brief
A Phase 2 clinical trial evaluating TUTI-16 (1.0 mg) and Placebo for HIV Infections. Completed, enrolled 27 participants across 1 site.
Detailed Summary
This protocol represents the third in human study of TUTI-16, and is being conducted to gather additional safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2011
Enrollment StartJun 2011
Primary CompletionJun 2012
TodayJul 2026
First PostedApr 14, 2011
Enrollment StartJun 1, 2011
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.2 years ago
Interventions
TUTI-16 (1.0 mg)biological
Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
Placeboother
Two subcutaneous injections of Placebo at Day 0 and Week 3.